CTF1 and glomerular disorder: There was a significant reduction in CTF1 mRNA levels in patients with lupus nephritis (p < 0.0001), vasculitis (p < 0.0001), IgA nephropathy (p = 0.002), membranous glomerulonephropathy (p = 0.007), minimal change disease (p = 0.005), focal segmental glomerulosclerosis (p < 0.0001) and arterial hypertension (p = 0.002), but not in patients with diabetic nephropathy (p = 0.139), indicating that CT‐1 signaling is downregulated in a range of human glomerular diseases.